OSRH · OSR Health, Inc. · Financials
3 customers — 95% of revenue
“Three main customers of RMC have in recent years represented approximately 95% of RMC's total sales.”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $1.81M | $2.91M | $3.53M | — | — | — | |
| $1.17M | $2.31M | $2.72M | — | — | — | |
| $100.19K | $97.53K | $113.47K | — | — | — | |
| $638.32K | $592.91K | $811.24K | — | — | — | |
| — | 20.4% | 22.98% | — | — | — | |
| $382.55K | $318.45K | $161.16K | — | — | — | |
| — | — | $3.52M | $1.83M | — | — | |
| $17.53M | $18.93M | $12.5M | $1.83M | $35.39K | $3308 | |
| $9.45M | $9.3M | $9.63M | — | — | — | |
| -$16.89M | -$18.34M | -$11.69M | -$1.83M | -$35.39K | -$3308 | |
| — | -631.01% | -331.2% | — | — | — | |
| $496.79K | $506.2K | $51.34K | — | — | — | |
| $53.97K | $63.88K | $21.29K | $2.78M | — | — | |
| — | — | $1.41M | $2.78M | — | — | |
| -$17.63M | -$28.89M | -$11.89M | $944.59K | — | — | |
| — | -$1.83M | -$1.56M | $540.81K | — | — | |
| -$14.91M | -$27.06M | -$2.41M | $403.78K | -$35.39K | -$3308 | |
| — | -931.19% | -68.29% | — | — | — | |
| — | -$9.05M | — | — | — | — | |
| -$10.73M | -$18.01M | -$10.33M | — | — | — | |
| -$17.45M | -$14.03M | -$10.28M | — | — | — | |
| USD/shares | -$0.01 | -$0.92 | -$4.79 | $0.05 | -$0.01 | — |
| USD/shares | — | -$0.80 | -$4.79 | $0.05 | -$0.01 | — |
| shares | — | 19.52M | 2.16M | 7.69M | 1.5M | 1.5M |
| shares | — | 22.56M | 2.16M | 7.72M | 1.5M | 1.5M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2023–FY2024: $72.23M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 153 similar-size Biotechnology companies (of 537 listed).